Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

14.61 (USD) • At close April 25, 2025
Bedrijfsnaam Arcutis Biotherapeutics, Inc.
Symbool ARQT
Munteenheid USD
Prijs 14.61
Beurswaarde 1,733,301,180
Dividendpercentage 0%
52-weken bereik 6.99 - 17.75
Industrie Biotechnology
Sector Healthcare
CEO Mr. Todd Franklin Watanabe M.A.
Website https://www.arcutis.com

An error occurred while fetching data.

Over Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam

Vergelijkbare Aandelen

Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc.

AXSM

106.27 USD

LeMaitre Vascular, Inc. logo

LeMaitre Vascular, Inc.

LMAT

91.61 USD

NeoGenomics, Inc. logo

NeoGenomics, Inc.

NEO

10.27 USD

Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc.

LYEL

0.45 USD

BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc.

BBIO

36.305 USD

Crinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc.

CRNX

32.39 USD

Veru Inc. logo

Veru Inc.

VERU

0.538 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)